证券代码：603139 证券简称：康惠制药 公告编号：2025-043 陕西康惠制药股份有限公司 关于为控股子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 担保对象及基本情况 （一）担保的基本情况 二、被担保人基本情况 （一）基本情况 ■ ● 累计担保情况 ■ 一、担保情况概述 ■ 三、担保协议的主要内容 1、保证合同 保证人：陕西康惠制药股份有限公司 2024年7月，贵阳银行股份有限公司成都都江堰支行（以下简称"贵阳银行"）向四川春盛药业集团股份 有限公司（以下简称"春盛药业"）提供借款500万元人民币，该笔借款将于2025年7月31日到期，公司作 为担保方，为该笔借款提供连带责任保证【具体内容详见公司于2024年8月1日在上海证券交易所网站 （www.sse.com.cn)披露的2024-036号公告】。近期，春盛药业就该笔借款申请了续贷，并于2025年7月 29日，与贵阳银行签署《流动资金借款合同》，借款期限自2025年7月30日至2026年7月12日止。公司与 贵阳银行签署《保 ...

证券代码：603139 证券简称：康惠制药 公告编号：2025-043 ? 担保对象及基本情况 陕西康惠制药股份有限公司 关于为控股子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 被担保人名称 | 四川春盛药业集团股份有限公司 | | --- | --- | | 本次担保金额 | 500 万元 | 担 保 | 对象 | 实际为其提供的担保余额 | 2,890 万元 | | | | --- | --- | --- | --- | --- | | | 是否在前期预计额度内 | ?是 | □否 | □不适用：_________ | | | 本次担保是否有反担保 | ?是 | □否 | □不适用：_________ | | ? | 累计担保情况 | | | | | | 对外担保逾期的累计金额（万元） | | | 0 | 截至本公告日上市公司及其控股子公司对外担保总额（万元） 11,871.84 对外担保总额占上市公司最近一期经审计净资产的比例（%） 13.85 一、担保情况概述 （一） 担保的 ...

证券日报网讯 7月29日晚间，康惠制药发布公告称，公司不存在对控股子公司（含控股孙公司）以外的 担保对象提供担保的情形；公司控股子公司（含控股孙公司）不存在对外担保的情形；公司及控股子公 司（含控股孙公司）不存在逾期担保情形。 （文章来源：证券日报） ...

证券代码：603139 证券简称：康惠制药 公告编号：2025-043 陕西康惠制药股份有限公司 关于为控股子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | | 被担保人名称 | | 四川春盛药业集团股份有限公司 | | | --- | --- | --- | --- | --- | | | 本次担保金额 | 500 | 万元 | | | 担 保 对象 | 实际为其提供的担保余额 | 2,890 | 万元 | | | | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | 本次担保是否有反担保 | 是 | □否 | □不适用：_________ | 担保对象及基本情况 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股子公司对外担保总额（万元） | 11,871.84 | | 对外担保总额占上市公司最近一期经审计净资产的比例（%） | 13.85 | 一、担保情况概述 （一） 担 ...

Core Viewpoint - A dramatic competition is unfolding in the capital market as Hunan Sailoxian Management Consulting Partnership successfully acquired a 24.47% stake in Qidi Pharmaceutical for 1.007 billion yuan, positioning itself as a potential new controlling shareholder [1][4][15] Group 1: Auction Details - The auction attracted eight bidders and garnered over 410,000 online viewers, with the bidding process extending to 138 rounds and 107 delays [5][6] - The starting price for the shares was approximately 450 million yuan, and the final bid represented a 124% premium over the starting price [7] - The auction price per share was about 17.19 yuan, while the closing price on the day of the auction was 13.86 yuan, indicating a significant price discrepancy [7] Group 2: Market Reactions - Following the auction, Qidi Pharmaceutical's stock experienced volatility, with a cumulative increase of 24.86% from July 9 to July 14, but a drop of 1.88% on July 15 [7][8] - The stock was listed on the Shenzhen Stock Exchange's "Dragon and Tiger List" due to its significant price fluctuations, with a notable sell-off from a specific brokerage [8][9] Group 3: Legal Context - The acquisition is set against a backdrop of a trademark infringement lawsuit initiated by Qidi Pharmaceutical against Hunan Hengchang Pharmaceutical, which is also linked to Hunan Sailoxian [10][11] - The lawsuit stems from allegations that Hengchang Pharmaceutical used Qidi's registered trademarks at a trade fair, leading to significant reputational damage for Qidi [10][11] Group 4: Financial Performance - Qidi Pharmaceutical has faced financial challenges, reporting a net loss of 125 million yuan in 2024 and an expected loss of 15 to 19 million yuan for the first half of the year [12] - The company's revenue has declined due to market conditions and rising material costs, impacting its overall profitability [12] Group 5: Future Implications - The potential acquisition raises questions about future asset injections and the strategic direction of Qidi Pharmaceutical under Hunan Sailoxian's control [16] - The relationship between Hunan Sailoxian and Hengchang Pharmaceutical may influence the resolution of ongoing legal disputes and the future operational strategy of Qidi Pharmaceutical [11][16]

Group 1 - Bailitianheng's innovative biopharmaceutical izabren (EGFR×HER3 dual-target ADC) has received approval for a Phase II clinical trial to treat advanced kidney cancer in combination with lenvatinib and pembrolizumab, potentially enhancing anti-tumor effects and addressing unmet needs in kidney cancer treatment [1] - Kanghui Pharmaceutical is involved in a legal dispute with Hubei Kelaivi regarding equity repurchase payments, with the latter appealing a first-instance ruling that ordered payment of 2 million yuan and 35.994 million yuan, highlighting risks in performance guarantees and repurchase clauses in pharmaceutical mergers [2] - *ST Suwu has announced an expected net loss of 60 million to 40 million yuan for the first half of 2025, primarily due to significant impairment provisions for trade receivables, indicating potential delisting risks if the company cannot return to profitability [3] - East China Pharmaceutical is exploring early projects targeting fat reduction and muscle health, aiming to capitalize on the global trend of GLP-1 drugs, although the projects are still in early exploration stages with significant uncertainties [4] - XW003 injection by Xianweida has initiated a new Phase II clinical trial comparing its efficacy and safety against semaglutide in obese patients, which could validate its unique cAMP-biased GLP-1 mechanism and accelerate entry into the weight loss market [5]

Group 1 - The company expects a net profit attributable to shareholders of approximately -38 million yuan for the first half of 2025, indicating a loss [2][4] - The estimated net profit attributable to shareholders, excluding non-recurring gains and losses, is approximately -41 million yuan for the same period [5] - The performance forecast period is from January 1, 2025, to June 30, 2025 [3] Group 2 - For the first half of 2024, the total profit was -9.88 million yuan, with a net profit attributable to shareholders of -8.70 million yuan [7] - The net profit attributable to shareholders, excluding non-recurring gains and losses, was -15.99 million yuan [7] - The earnings per share for the first half of 2024 was -0.09 yuan [8] Group 3 - The primary reasons for the expected loss include increased costs and expenses due to changes in pharmaceutical policies and industry environment [9] - The company is actively adjusting its business strategy to focus on sales and expand its market presence in community hospitals, clinics, and pharmacies [9] - The subsidiary, Shaanxi Youbang Biomedical Technology Co., Ltd., is experiencing significant depreciation and financing costs, along with unfavorable market conditions, contributing to the overall loss [9] Group 4 - The company has received a civil appeal regarding a lawsuit related to a share repurchase agreement, with the amount involved being approximately 37.99 million yuan plus interest [16] - The company is currently in the stage of receiving the appeal, and the outcome of the lawsuit remains uncertain [14][16] - The company will fulfill its information disclosure obligations based on the progress of the lawsuit [16]

证券代码：603139 证券简称：康惠制药 公告编号：2025-042 陕西康惠制药股份有限公司 关于收到《民事上诉状》暨诉讼进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 案件所处的诉讼阶段：收到上诉状 ● 是否会对上市公司损益产生影响：因目前仅收到上诉状，二审受理及具 体开庭时间尚未明确，诉讼结果存在不确定性，公司暂无法准确判断本次诉讼进 展对公司本期或期后利润的影响。 一、本次诉讼的基本情况 陕西康惠制药股份有限公司（以下简称"公司"）就要求与湖北科莱维生物 药业有限公司（以下简称"科莱维"）支付股权回购定金及股权回购款事项于 2024年9月向陕西省咸阳市秦都区人民法院提起诉讼，具体内容详见公司于2024 年 9 月 21 日在上海证券交易所网站（www.sse.com.cn）披露的《陕西康惠制药 股份有限公司关于科莱维回购公司所持其 42.8725%股权进展暨公司提起诉讼的 公告》（公告编号：2024-048）。 2025 年 5 月 16 日，公司收到陕西省咸阳市秦都区人民法院《民事判 ...

[Performance Forecast Overview](index=1&type=section&id=Performance%20Forecast%20Overview) The company anticipates a significant loss for the first half of 2025, with specific net profit figures provided for both attributable and non-recurring adjusted results [Key Highlights](index=1&type=section&id=Key%20Highlights) Shaanxi Kanghui Pharmaceutical Co., Ltd. expects a loss for the first half of 2025, with net profit attributable to shareholders estimated at approximately -38 million RMB and net profit attributable to shareholders after deducting non-recurring gains and losses estimated at approximately -41 million RMB Estimated Financial Performance for H1 2025 | Indicator | Estimated Amount (Million RMB) | | :--- | :--- | | Net Profit Attributable to Parent Company Shareholders | -38 | | Net Profit Attributable to Parent Company Shareholders After Deducting Non-Recurring Gains/Losses | -41 | | Impact of Non-Recurring Gains/Losses | 2.6 | - The company anticipates a **loss for the first half of 2025**[3](index=3&type=chunk) [Current Period Performance Forecast](index=1&type=section&id=Current%20Period%20Performance%20Forecast) The company specified the performance forecast period for the first half of 2025 as January 1 to June 30, reiterated the projected loss figures, and emphasized that this forecast is a preliminary estimate unaudited by an accounting firm - The performance forecast period is **January 1, 2025, to June 30, 2025**[4](index=4&type=chunk) Key Estimated Financial Indicators for H1 2025 | Indicator | Estimated Amount (Million RMB) | | :--- | :--- | | Net Profit Attributable to Parent Company Shareholders | -38 | | Net Profit Attributable to Parent Company Shareholders After Deducting Non-Recurring Gains/Losses | -41 | - This performance forecast is a preliminary estimate based on the company's operating conditions and has **not been audited by an accounting firm**[6](index=6&type=chunk) [H1 2024 Performance Review](index=1&type=section&id=H1%202024%20Performance%20Review) This section reviews the company's financial performance for the first half of 2024, highlighting the previously incurred losses as a comparative context [H1 2024 Performance Details](index=1&type=section&id=H1%202024%20Performance%20Details) The company disclosed its financial data for the first half of 2024, indicating a prior loss state, which serves as a comparative baseline for the current period's projected loss, with net profit attributable to parent company shareholders at **-8.7020 million RMB** H1 2024 Financial Performance | Indicator | H1 2024 Amount (Million RMB) | | :--- | :--- | | Total Profit | -9.8818 | | Net Profit Attributable to Parent Company Shareholders | -8.7020 | | Net Profit After Deducting Non-Recurring Gains/Losses | -15.9866 | | Earnings Per Share (RMB) | -0.09 | [Analysis of Main Reasons for Projected Loss](index=2&type=section&id=Analysis%20of%20Main%20Reasons%20for%20Projected%20Loss) This section analyzes the primary factors contributing to the projected loss, including increased parent company costs and significant losses from a controlled subsidiary [Increase in Parent Company Costs and Expenses](index=2&type=section&id=Increase%20in%20Parent%20Company%20Costs%20and%20Expenses) Influenced by pharmaceutical policies and industry conditions, the parent company actively adjusted its operating strategy, expanded sales channels (including secondary and tertiary terminals), and optimized product structure (increasing sales of agency products), leading to a significant increase in costs and expenses in H1 2025 compared to the previous year, thus impacting overall performance - Affected by pharmaceutical policies and industry environment, the company actively adjusted its operating strategy, maintaining a **sales-centric approach**[8](index=8&type=chunk) - The company continues to consolidate hospital sales and vigorously expand **secondary and tertiary terminal sales** such as community hospitals, clinics, and pharmacies[8](index=8&type=chunk) - The company adjusted its sales product structure, increasing sales of agency products, which led to a **significant increase in costs and expenses** in H1 2025 compared to the previous year[8](index=8&type=chunk) [Impact of Losses from Controlled Subsidiary](index=2&type=section&id=Impact%20of%20Losses%20from%20Controlled%20Subsidiary) Controlled subsidiary Shaanxi Youbang Biomedical Technology Co., Ltd. incurred significant fixed asset depreciation and financing loan interest expenses, coupled with unexpected product market supply-demand changes leading to lower-than-expected revenue, resulting in substantial losses in H1 2025 and a significant impact on the company's current period performance - Controlled subsidiary Shaanxi Youbang Biomedical Technology Co., Ltd. incurred **significant fixed asset depreciation and financing loan interest expenses**[8](index=8&type=chunk) - Shaanxi Youbang's product market supply and demand relationship is highly volatile, leading to **lower-than-expected product revenue**[8](index=8&type=chunk) - Shaanxi Youbang continued to incur **substantial losses in H1 2025**, impacting the company's current period performance[8](index=8&type=chunk) [Risk Warning and Disclosures](index=2&type=section&id=Risk%20Warning%20and%20Disclosures) This section provides crucial risk warnings and disclosures, emphasizing the preliminary nature of the financial forecast and advising investors to exercise caution [Risk Warning](index=2&type=section&id=Risk%20Warning) The company reiterates that this performance forecast is a preliminary calculation based on the finance department's professional judgment and has not been audited by a certified public accountant, reminding investors to be aware of potential investment risks - This performance forecast is a preliminary calculation by the company's finance department based on its professional judgment and has **not yet been audited by a certified public accountant**[9](index=9&type=chunk) [Other Disclosures](index=2&type=section&id=Other%20Disclosures) The company reminds investors that the performance forecast data is only a preliminary calculation, and the final accurate financial data will be subject to the company's officially disclosed '2025 Semi-Annual Report,' reiterating investment risks - The performance forecast data above is only preliminary; the **final accurate financial data will be based on the company's officially disclosed '2025 Semi-Annual Report'**[10](index=10&type=chunk) - Investors are kindly reminded to **pay attention to investment risks**[10](index=10&type=chunk)

Investment Rating - The industry maintains an "Overweight" rating, suggesting a positive outlook for investment opportunities in the Chinese medicine sector [6]. Core Insights - The Chinese medicine sector saw a 1.08% increase last week, with the overall pharmaceutical sector experiencing a general upward trend [2]. - The price-to-earnings (PE) ratio for the Chinese medicine sector is 27.86X, reflecting a slight increase, while the price-to-book (PB) ratio stands at 2.31X, also showing a minor rise [3]. - The market for Chinese medicinal materials is currently in a low season, with a slight decline in price indices due to increased rainfall in southern regions [4]. - As of July 12, 2025, three out of five listed companies in the Chinese medicine industry reported positive net profit growth, with the lowest growth rate at 24.3% [5]. Summary by Sections Market Performance - The Chinese medicine sector index closed at 6451.72 points, up 1.08% last week, while the overall pharmaceutical index rose by 1.82% [2][17]. Valuation - The PE ratio (ttm) for the Chinese medicine sector is 27.86X, up 0.29X week-on-week, with a one-year maximum of 30.13X and a minimum of 22.58X. The PB ratio (lf) is 2.31X, up 0.03X, with a one-year maximum of 2.65X and a minimum of 1.99X [3][19]. Industry Trends - The Chinese medicine sector is entering the mid-year reporting season, with a focus on performance metrics such as inventory and accounts receivable [5]. - The report highlights three main investment themes: price governance, consumption recovery, and state-owned enterprise reform, indicating potential growth areas within the sector [6][9]. Investment Recommendations - Recommended companies include those with strong R&D capabilities and unique products, as well as those less affected by price collection policies. Specific companies highlighted are Zhaoli Pharmaceutical, Pizaihuang, and Shouxiangu [10].